Tufts Center for the Study of Drug Development reported that an AI clinical monitoring agent could generate up to 82 times return on investment (ROI) in oncology trials, using expected net present value (eNPV) modeling based on benchmark and actual use data from Medable’s platform. The analysis projected net financial gains as high as $21 million per drug development program in Phase 3. Tufts estimated eNPV gains of about $7.5 million in Phase 2, $11.3 million across combined Phase 2/3 programs, and $21 million in Phase 3—driven by efficiencies such as reduced on-site visits and travel costs, accelerated enrollment, and shorter database lock timelines. The report also projected 18-week overall development acceleration and substantial administrative off-site monitoring savings. While the figures are financial-model outputs rather than clinical efficacy endpoints, the study spotlights how agentic AI is being positioned to change clinical trial economics—especially for sponsors managing multi-study oncology portfolios.